Advertisement

Emerging Theranostic Silver and Gold Nanomaterials to Combat Prostate Cancer: A Systematic Review

  • Hamed BarabadiEmail author
  • Kaveh Damavandi Kamali
  • Fereshteh Jazayeri Shoushtari
  • Babak Tajani
  • Mohammad Ali Mahjoub
  • Ahad Alizadeh
  • Muthupandian SaravananEmail author
Review Paper
  • 19 Downloads

Abstract

Prostate cancer has emerged as the common malignancy in men and is considered as a global issue. Among different strategies to combat prostate cancer, nanobiotechnology appears as a novel approach for prostate cancer theranostics. The current systematic review discussing the recent development in the prostate anticancer activity of biologically synthesized silver nanoparticles (AgNPs) and gold nanoparticles (AuNPs) through laboratory investigations. The databases including Cochrane, Web of Science, PubMed, Scopus, Science Direct, ProQuest, and Embase were used to identify the records. It was found that most of the studies used herbal extracts for preparation of AgNPs and/or AuNPs. Majority of biosynthesized nanoparticles (NPs) were formed with spherical morphology. Besides, all studies reported the size of NPs less than 100 nm. Moreover, PC-3 prostate cancer cell was the predominant cell line that was evaluated for prostate anticancer activity of NPs. In the present study, we provided valuable information suggesting the significant prostate anticancer potential of biogenic AgNPs and/or AuNPs. However, further, in vivo investigations are required to provide stronger evidence of the efficacy of bio-mediated synthesized AgNPs and/or AuNPs to combat prostate cancer.

Keywords

Prostate cancer Cancer nanomedicine Silver nanoparticles Gold nanoparticles 

Notes

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    S. Zaidi, J. Gandhi, G. Joshi, N. L. Smith, and S. A. Khan (2019). Prostate Cancer Prostatic Dis..  https://doi.org/10.1038/s41391-018-0085-2.Google Scholar
  2. 2.
    O. Sartor and J. S. de Bono (2018). N. Engl. J. Med. 378, 645.CrossRefGoogle Scholar
  3. 3.
    R. L. Siegel, K. D. Miller, and A. Jemal (2019). CA Cancer J. Clin. 69, 7.CrossRefGoogle Scholar
  4. 4.
    American Cancer Society Cancer Facts & Figures 2019 (American Cancer Society, Atlanta, 2019).Google Scholar
  5. 5.
    J. Ferlay, M. Colombet, I. Soerjomataram, T. Dyba, G. Randi, M. Bettio, A. Gavin, O. Visser, and F. Bray (2018). Eur. J. Cancer 103, 356.CrossRefGoogle Scholar
  6. 6.
    D. Cunningham and Z. You (2015). J. Biol. Methods 2, e17.CrossRefGoogle Scholar
  7. 7.
    J. C. Henegan and G. Sonpavde (2018). Exp. Opin. Biol. Ther. 18, 109.CrossRefGoogle Scholar
  8. 8.
    V. K. Lakshmanan (2016). Investig. Clin. Urol. 57, 21.CrossRefGoogle Scholar
  9. 9.
    H. Barabadi, M. A. Mahjoub, B. Tajani, A. Ahmadi, Y. Junejo, and M. Saravanan (2019). J. Clust. Sci. 30, 259.CrossRefGoogle Scholar
  10. 10.
    H. Barabadi (2017). Cell. Mol. Biol. 63, 3.CrossRefGoogle Scholar
  11. 11.
    H. Barabadi, F. Kobarfard, and H. Vahidi (2018). Iran J. Pharm. Res. 17, 87.Google Scholar
  12. 12.
    H. Barabadi, A. Alizadeh, M. Ovais, A. Ahmadi, Z. K. Shinwari, and M. Saravanan (2018). IET Nanobiotechnol. 12, 377.CrossRefGoogle Scholar
  13. 13.
    H. Barabadi, M. Ovais, Z. K. Shinwari, and M. Saravanan (2017). Green Chem. Lett. Rev. 10, 285.CrossRefGoogle Scholar
  14. 14.
    H. Barabadi, S. Honary, P. Ebrahimi, M. A. Mohammadi, A. Alizadeh, and F. Naghibi (2014). Braz. J. Microbiol. 45, 1493.CrossRefGoogle Scholar
  15. 15.
    H. Barabadi, Z. Alizadeh, M. T. Rahimi, A. Barac, A. E. Maraolo, L. J. Robertson, A. Masjedi, F. Shahrivar, and E. Ahmadpour (2019). Nanomedicine: NBM 18, 221.CrossRefGoogle Scholar
  16. 16.
    N. Karimi, A. Chardoli, and A. Fattahi (2017). Iran. J. Pharm. Res. 16, 1167.Google Scholar
  17. 17.
    S. Salari, S. Esmaeilzadeh Bahabadi, A. Samzadeh-Kermani, and F. Yousefzaei (2019). Iran. J. Pharm. Res. 18, 430.Google Scholar
  18. 18.
    Z. Rezvani Amin, Z. Khashyarmanesh, B. S. Fazly Bazzaz, and Z. Sabeti Noghabi (2019). Iran. J. Pharm. Res. 18, 210.Google Scholar
  19. 19.
    T. Ramezani, M. Nabiuni, J. Baharara, K. Parivar, and F. Namvar (2019). Iran. J. Pharm. Res. 18, 222.Google Scholar
  20. 20.
    M. M. Or Rashid, M. S. Islam, M. A. Haque, M. A. Rahman, M. T. Hossain, and M. A. Hamid (2016). Iran. J. Pharm. Res. 15, 591.Google Scholar
  21. 21.
    R. Dobrucka (2017). Iran. J. Pharm. Res. 16, 753.Google Scholar
  22. 22.
    Q. Abbas, M. Saleem, A. R. Phull, M. Rafiq, M. Hassan, K.-H. Lee, and S.-Y. Seo (2017). Iran. J. Pharm. Res. 16, 760.Google Scholar
  23. 23.
    H. Barabadi, B. Tajani, M. Moradi, K. Damavandi Kamali, R. Meena, S. Honary, M. A. Mahjoub, and M. Saravanan (2019). J. Clust. Sci..  https://doi.org/10.1007/s10876-019-01554-3.Google Scholar
  24. 24.
    P. Boomi, G. P. Poorani, S. Palanisamy, S. Selvam, G. Ramanathan, S. Ravikumar, H. Barabadi, H. G. Prabu, J. Jeyakanthan, and M. Saravanan (2019). J. Clust. Sci. 30, 715.CrossRefGoogle Scholar
  25. 25.
    K. Rasmussen, H. Rauscher, A. Mech, J. Riego Sintes, D. Gilliland, M. Gonzalez, P. Kearns, K. Moss, M. Visser, M. Groenewold, and E. A. J. Bleeker (2018). Regul. Toxicol. Pharmacol. 92, 8.CrossRefGoogle Scholar
  26. 26.
    B. D. Chithrani, A. A. Ghazani, and W. C. Chan (2006). Nano Lett. 6, 662.CrossRefGoogle Scholar
  27. 27.
    S. Hauert and S. N. Bhatia (2014). Trends Biotechnol. 32, 448.CrossRefGoogle Scholar
  28. 28.
    M. S. Bethu, V. R. Netala, L. Domdi, V. Tartte, and V. R. Janapala (2018). Artif. Cells Nanomed. Biotechnol. 46, S104.CrossRefGoogle Scholar
  29. 29.
    M. S. Bethu and J. Venkateswara Rao (2017). Asian J. Pharm. Clin. Res. 10, 65.CrossRefGoogle Scholar
  30. 30.
    A. Parveen and S. Rao (2015). J. Clust. Sci. 26, 775.CrossRefGoogle Scholar
  31. 31.
    E. B. El Domany, T. M. Essam, A. E. Ahmed, and A. A. Farghali (2018). J. Appl. Pharm. Sci. 8, 119.CrossRefGoogle Scholar
  32. 32.
    K. Kalaiarasi, G. Prasannaraj, S. V. Sahi, and P. Venkatachalam (2015). Turk. J. Biol. 39, 223.CrossRefGoogle Scholar
  33. 33.
    G. Prasannaraj, S. V. Sahi, S. Ravikumar, and P. Venkatachalam (2016). J. Nanosci. Nanotechnol. 16, 4948.CrossRefGoogle Scholar
  34. 34.
    G. Prasannaraj and P. Venkatachalam (2017). Adv. Nat. Sci. Nanosci. 8, 025001.CrossRefGoogle Scholar
  35. 35.
    K. Rajathi, N. Kannikaparameswari, and S. Suja (2017). Eur. J. Pharm. Sci. 4, 401.Google Scholar
  36. 36.
    H. Barabadi, S. Honary, M. Ali Mohammadi, E. Ahmadpour, M. T. Rahimi, A. Alizadeh, F. Naghibi, and M. Saravanan (2017). Environ. Sci. Pollut. Res. Int. 24, 5800.CrossRefGoogle Scholar
  37. 37.
    M. J. Firdhouse and P. Lalitha (2013). Cancer Nanotechnol. 4, 137.CrossRefGoogle Scholar
  38. 38.
    Y. He, Z. Du, S. Ma, S. Cheng, S. Jiang, Y. Liu, D. Li, H. Huang, K. Zhang, and X. Zheng (2016). Nanoscale Res. Lett. 11, 300.CrossRefGoogle Scholar
  39. 39.
    Y. Q. He, X. Li, Y. Y. Zheng, Z. Y. Wang, Z. Y. Ma, Q. Yang, B. H. Yao, Y. J. Zhao, and H. Zhang (2018). New J. Chem. 42, 2882.CrossRefGoogle Scholar
  40. 40.
    J. Raman, G. R. Reddy, H. Lakshmanan, V. Selvaraj, B. Gajendran, R. Nanjian, A. Chinnasamy, and V. Sabaratnam (2015). Process Biochem. 50, 140.CrossRefGoogle Scholar
  41. 41.
    Y. Q. He, X. Li, J. Wang, Q. Yang, B. H. Yao, Y. J. Zhao, A. M. Zhao, W. X. Sun, and Q. Zhang (2017). Environ. Toxicol. Pharmacol. 56, 56.CrossRefGoogle Scholar
  42. 42.
    R. E. Heravi, S. Zakeri, and P. Nazari (2018). Micro Nano Lett. 13, 1475.CrossRefGoogle Scholar
  43. 43.
    K. Jadhav, S. Deore, D. Dhamecha, H. R. Rajeshwari, S. Jagwani, S. Jalalpure, and R. Bohara (2018). ACS Biomater. Sci. Eng. 4, 892.CrossRefGoogle Scholar
  44. 44.
    D. G. Kumar, N. S. Raj, R. Kumar, and K. S. Nagendra (2017). Int. Res. J. Pharm. 8, 109.Google Scholar
  45. 45.
    R. I. Priyadharshini, G. Prasannaraj, N. Geetha, and P. Venkatachalam (2014). Appl. Biochem. Biotechnol. 174, 2777.CrossRefGoogle Scholar
  46. 46.
    O. S. Adeyemi and F. A. Sulaiman (2015). J. Biomed. Res. 29, 145.Google Scholar
  47. 47.
    K. M. Ardhendu (2017). Glob. J. Nanomed. 3, 555607.Google Scholar
  48. 48.
    S. Khalid and R. Hanif (2017). IJASET 5, 59.Google Scholar
  49. 49.
    M. Naz, N. Nasiri, M. Ikram, M. Nafees, M. Z. Qureshi, S. Ali, and A. Tricoli (2017). Appl. Nanosci. 7, 793.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmaceutical Biotechnology, School of PharmacyShahid Beheshti University of Medical SciencesTehranIran
  2. 2.Golestan University of Medical Sciences, Food and Drug AdministrationGorganIran
  3. 3.School of PharmacyAhvaz Jundishapur University of Medical SciencesAhvazIran
  4. 4.Department of Pharmaceutics, School of PharmacyShahid Beheshti University of Medical SciencesTehranIran
  5. 5.Department of Epidemiology and Biostatistics, School of Public HealthTehran University of Medical SciencesTehranIran
  6. 6.Department of Medical Microbiology and Immunology, Division of Biomedical Sciences, School of Medicine, College of Health SciencesMekelle UniversityMekelleEthiopia

Personalised recommendations